Flagship Pioneering

Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory Boards

Retrieved on: 
星期二, 五月 28, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Biogen, Shionogi, Annamalai University, General partnership, Genentech, Biochemistry, Sarepta Therapeutics, Takeda Oncology, Biofilm, Flagship Pioneering, Palani, University, Therapy, Virginia Commonwealth University, Infection, MBA, Biophysics, MD, Takeda Pharmaceutical Company, Executive, Management

Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.

Key Points: 
  • Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.
  • His early career included leadership positions at Millennium Pharmaceuticals (acquired by Takeda), Biogen, Nexstar Pharmaceuticals (acquired by Gilead), and Par Pharmaceuticals.
  • He is currently a Managing Partner and Co-Founder of Trekk Venture Partners and serves on multiple public and private company boards.
  • Mr. Westberg received his MBA from the University of California, Berkeley and his BA from the University of California, San Diego.

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

Retrieved on: 
星期三, 五月 22, 2024
Jefferies, Evercore, Investment, Patient, Therapy, Gene expression, Flagship Pioneering

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its previously announced registered direct offering of common stock and of pre-funded warrants, with gross proceeds of the offering totaling approximately $110 million. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
  • The offering includes new investors BVF Partners, Deerfield Management and other leading healthcare specialist investors as well as other new and previous investors, including founding investor Flagship Pioneering.
  • Jefferies, TD Cowen and Evercore ISI acted as joint book-running managers for the offering.
  • “This financing allows us to advance our programs through multiple data readouts and clinical value inflection points as we continue to develop medicines for patients and create value for shareholders.

Meatable Appoints U.S.-Based Meat Industry Veteran Jeff Tripician as New CEO

Retrieved on: 
星期三, 五月 22, 2024
Restaurant, Bar, Food, Beverage, Retail, Food Tech, Technology, Cattle, Meat, Transport, Rest, Eating, Biology, Niman Ranch, Protein, Flagship Pioneering, Soil, Food security, Farmer, Climate change, Krijn, Growth, Medicine, Acquisition, Perdue, Environment, Biotechnology, History, Agriculture, Multimedia, Preme, Tyson Foods

Meatable, the innovative food tech company on a mission to deliver cultivated meat at scale, today announced the appointment of Jeff (“Trip”) Tripician as CEO, effective June 17.

Key Points: 
  • Meatable, the innovative food tech company on a mission to deliver cultivated meat at scale, today announced the appointment of Jeff (“Trip”) Tripician as CEO, effective June 17.
  • Mr. Tripician succeeds current CEO and co-founder Krijn de Nood, who will continue to serve on the Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20240522001501/en/
    Meatable appoints U.S.-based meat industry veteran Jeff (“Trip”) Tripician as new CEO (Photo: Business Wire)
    Mr. Tripician, an industry veteran with more than 25 years of experience in the organic and natural meat industry in the U.S., will lead Meatable as it prioritizes U.S. market expansion.
  • “Meatable has enormous potential to disrupt the cultivated meat space with its unique approach to product development and commercialization,” said Mr. Banks.

Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management

Retrieved on: 
星期四, 五月 9, 2024
Flagship Pioneering, Machine learning, Partnership, Research, Flagship, Obesity, Disease, Therapy, Novo Nordisk, Panasonic Executive Partner, Molecular mimicry, Biology, Drug development, MIMIC

CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today joined Flagship Pioneering in announcing a research collaboration with Novo Nordisk to develop up to two next-generation therapeutics for obesity management.

Key Points: 
  • The collaboration is signed under the broader strategic partnership between Novo Nordisk and Flagship Pioneering to develop a portfolio of novel treatment approaches for cardiometabolic and rare diseases.
  • Metaphore will work jointly with Pioneering Medicines and Novo Nordisk to advance the programs through foundational activities and preclinical development, after which point Novo Nordisk could advance the programs into clinical studies.
  • Metaphore is the third Flagship-founded company to advance research programs under the strategic partnership between Novo Nordisk and Flagship Pioneering following programs with Omega Therapeutics and Cellarity which were announced earlier this year.
  • Novo Nordisk will also reimburse R&D costs and participate in a future financing round for Metaphore.

Ring Therapeutics Presents New Data on Anellogy™ Platform at the 27th Annual American Society of Gene & Cell Therapy Conference

Retrieved on: 
星期二, 五月 7, 2024
Commensalism, AMD, Flagship Pioneering, Tropism, MD, Cell, AAV, Eye, Potential, Real-time, Human, DNA, Patient, Gene, Immune system, ANV, MBA, NHP, Therapy, Vaccine

CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced new preclinical data demonstrating successful transduction and redosability of its Anellovector within non-human primates, as well as expanded payload capacity for the vector beyond the natural genome size of anelloviruses (ANV). The data, which will be presented as one oral presentation and two posters at the 27th Annual America Society of Gene & Cell Therapy (ASGCT) conference, showcases the viability of Anellovectors as the next generation of viral vectors.

Key Points: 
  • The data, which will be presented as one oral presentation and two posters at the 27th Annual America Society of Gene & Cell Therapy (ASGCT) conference, showcases the viability of Anellovectors as the next generation of viral vectors.
  • Additionally, the expanded payload capacity of Anellovectors widens the therapeutic potential of this novel vector class allowing even more patients to be potentially treated.
  • Unlike AAV, which appears to exhibit a strict packaging limit, Anellovectors allow for the packaging of genomes larger than the wild-type genome.
  • A combination of qPCR and next-generation sequencing was used to verify that the encapsidated expanded cargo DNA is intact, circular, and single-stranded.

Cellarity Appoints Head of Platform to Advance Vision for Novel Drug Creation

Retrieved on: 
星期二, 五月 7, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Health Technology, Sickle cell disease, University, Flagship Pioneering, SCD, Machine learning, Life, IND, Novo Nordisk, Chemistry, Biology, Pharming, Multimedia, Drug development, Genomics, Drug discovery, MASH, Head, Pharmaceutical industry

In this role, Woelk will lead Cellarity’s revolutionary platform to create drugs that are presently out of reach with traditional methods of drug discovery.

Key Points: 
  • In this role, Woelk will lead Cellarity’s revolutionary platform to create drugs that are presently out of reach with traditional methods of drug discovery.
  • The Cellarity platform uses proprietary AI models to link biology and chemistry with high-dimensional multi-omic data to uncover novel actionable insights into disease biology and create non-intuitive drug candidates in a vast array of clinical conditions.
  • “Topher’s experience is particularly relevant to Cellarity as we continue to invest in our platform.
  • “I look forward to helping advance the platform by bringing to life insights that will open up opportunities for new drug development programs and help accelerate the company’s pipeline towards the clinic.”

Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome

Retrieved on: 
星期二, 五月 7, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Doctor of Philosophy, Protein, Flagship Pioneering, Viral, Machine learning, Proteome, Entrepreneurship, Disease, Physiology, Virus, Database, MBA, Strategy, Vaccine

Flagship Pioneering, the bioplatform innovation company, today unveiled Prologue Medicines, a company unlocking the therapeutic potential of the viral proteome for the creation of powerful new medicines.

Key Points: 
  • Flagship Pioneering, the bioplatform innovation company, today unveiled Prologue Medicines, a company unlocking the therapeutic potential of the viral proteome for the creation of powerful new medicines.
  • "We asked, what if we could expand beyond the functional boundaries of the human proteome by harnessing viral evolution,” said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of the Strategic Oversight Board of Prologue.
  • “By exploring the viral proteome, we can discover novel proteins with enhanced or completely unique therapeutic properties to develop medicines for optimal patient outcomes.”
    Prologue is unlocking viral proteome-assisted drug discovery with its novel DELVE Platform.
  • “The viral proteome dwarfs the human proteome by orders of magnitude, enabling us to reveal a trove of powerful new proteins that can be used as medicines across nearly any therapeutic area,” said Lovisa Afzelius, Ph.D., MBA, Co-Founder and CEO of Prologue and Origination Partner at Flagship Pioneering.

Alltrna Applies Machine Learning to Engineer tRNA Oligonucleotides with Significantly Improved Activity and Demonstrates In Vivo Readthrough of the Two Most Common Premature Termination Codons in Genetic Disease

Retrieved on: 
星期二, 五月 7, 2024
Small RNA, Mutation, Flagship Pioneering, LNP, Machine learning, RNA, Cell, Molecular biology, Computation, Disease, Oligonucleotide, Therapy, Gene, Society, Biology, Annual general meeting, PTC

"The data demonstrate the power of Alltrna's platform to identify key combinations of tRNA sequences and modifications and precisely design tRNA oligonucleotides with significantly improved in vivo activity.

Key Points: 
  • "The data demonstrate the power of Alltrna's platform to identify key combinations of tRNA sequences and modifications and precisely design tRNA oligonucleotides with significantly improved in vivo activity.
  • With optimized engineered tRNAs for the two most prevalent premature termination codons, we are advancing preclinical studies for our first Stop Codon Disease indications."
  • Delivered using a liver-directed lipid nanoparticle (LNP), both optimized tRNAs showed robust in vivo activity in two transgenic mouse models.
  • "We've also demonstrated that we can engineer robust tRNA activity for two different premature termination codons, each of which are highly prevalent in Stop Codon Disease."

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

Retrieved on: 
星期一, 四月 29, 2024
Doctor of Philosophy, Flagship Pioneering, BMY, Epitope, Research, Vaccine, Repertoire, Disease, Autoimmune disease, Patient, Immunology, BMS, Immune system, Bristol Myers Squibb, TCR, Biotechnology, Pharmaceutical industry

CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.

Key Points: 
  • CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases.
  • The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.
  • "We are excited to collaborate with Bristol Myers Squibb to combine their leadership in immunology with our unique ability to discover key disease-associated epitopes in patients with autoimmune diseases.
  • This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease."

Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy

Retrieved on: 
星期一, 四月 22, 2024
Tropism, Therapy, Flagship Pioneering, Baltimore Convention Center, Gene, Society, Cell, Conference, Vaccine

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced an oral presentation and two poster presentations at the 27th Annual American Society of Gene & Cell Therapy (ASGCT) Conference, to be held in Baltimore, Maryland from May 7 – 11, 2024. These presentations showcase the immense promise of a new class of viral vectors from Ring’s Anellogy™ platform to overcome some of the largest barriers associated with delivery of current genetic medicines including redosability and tissue tropism.

Key Points: 
  • CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics , a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced an oral presentation and two poster presentations at the 27th Annual American Society of Gene & Cell Therapy (ASGCT) Conference, to be held in Baltimore, Maryland from May 7 – 11, 2024.
  • These presentations showcase the immense promise of a new class of viral vectors from Ring’s Anellogy™ platform to overcome some of the largest barriers associated with delivery of current genetic medicines including redosability and tissue tropism.
  • Session Title and Location: Emerging Viral Vectors – Ballroom 4, Baltimore Convention Center